In a prospective study including 123 patients under platinum chemotherapeutics, urinary levels of KIM-1, NGAL, and cystatin C showed statistically significant elevation at day three after treatment initiation in AKI patients. This evidence concerns the gene HAVCR1 and acute kidney injury.